A.01 Relieving the burden of myasthenia gravis: eculizumab reduces exacerbation, hospitalization and rescue therapy rates
Siddiqi Z, Howard J, Jacob S, Guptill J, Meisel A, Wiendl H, Murai H, Utsugisawa K, Nowak R, Fujita K, O’Brien F, Patra K, Muppidi S. A.01 Relieving the burden of myasthenia gravis: eculizumab reduces exacerbation, hospitalization and rescue therapy rates. Canadian Journal Of Neurological Sciences / Journal Canadien Des Sciences Neurologiques 2019, 46: s8-s8. DOI: 10.1017/cjn.2019.83.Peer-Reviewed Original ResearchPre-study yearOpen-label extensionHealthcare resource utilizationMyasthenia gravisEculizumab treatmentDisease burdenSignificant healthcare resource utilizationAnti-acetylcholine receptorExacerbations/hospitalizationsGreater disease burdenPoisson regression modelsMG crisisTherapy ratesRescue therapyResponsive patientsTherapy useTherapy usageClinical endpointsExacerbationHospitalizationPatientsMeaningful benefitREGAIN studyPatient recordsEvent rates